Yayınlar & Eserler

Yayın Ağı
Makaleler 184
Tümü (184)
SCI-E, SSCI, AHCI (137)
SCI-E, SSCI, AHCI, ESCI (164)
ESCI (8)
Scopus (167)
TRDizin (25)
Diğer Yayınlar (6)

1. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

Yildirim H. C., BAYRAM E., Chalabiyev E., Majidova N., Avci T., Guzel H. G., et al.
JOURNAL OF CHEMOTHERAPY , cilt.37, sa.6, ss.551-562, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

2. Evaluation of implementation of evolving practice patterns in the first-line treatment of patients with metastatic non-small cell lung cancer in Turkiye (ESTIMATE): a national, multicenter, retrospective, real-world evidence study

ŞENDUR M. A. N., Karadurmus N., ÇİÇİN İ., GÜMÜŞ M., Demirci U., ÖZYILKAN Ö., et al.
FUTURE ONCOLOGY , cilt.21, sa.19, ss.2525-2535, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

3. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC

Yildirim M. E., Karadurmus N., Okten I. N., TÜRK H. M., URAKÇI Z., Arslan C., et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE , cilt.31, sa.3, ss.404-411, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

4. Understanding of Clinical Trials Among Patients With Cancer and Their Relatives

KUBİLAY TOLUNAY P., Erol C., Kahraman S., Tacar S. Y., ÖZCAN E., Basal F. B., et al.
JAMA NETWORK OPEN , cilt.8, sa.1, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

5. Perceptions and Expectations: A Study on Prognostic Perception and Quality of Life in Patients With Metastatic Renal and Bladder Cancer

Bolek H., Arslan C., Basaran M., ÇİÇİN İ., ÖZGÜROĞLU M., Tural D., et al.
JCO GLOBAL ONCOLOGY , cilt.10, 2024 (ESCI, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

6. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study

ÇİÇİN İ., Plimack E. R., Gurney H., Leibowitz R., Alekseev B. Y., Parnis F. X., et al.
BMC Cancer , cilt.23, sa.Suppl 1, 2024 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

7. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy

Kilickap S., Ozturk A., Karadurmus N., KORKMAZ T., Yumuk P. F., ÇİÇİN İ., et al.
MEDICINE , cilt.103, sa.21, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

8. Is the "P-value" Alone a Sufficient Metric for the Magnitude of Clinical Benefit and Which Clinical Trial Is Actually Positive, KEYNOTE-394 or KEYNOTE-240?

KUŞ T., Aktas G., ÇİÇİN İ.
ONCOLOGIST , cilt.29, sa.3, ss.190-191, 2024 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier

9. Impact of Dose Reductions on Efficacy of Adjuvant Abemaciclib for Patients with High Risk Early Breast Cancer (EBC): Analyses from the monarchE Study

Zaiss M., O'shaughnessy J., ÇİÇİN İ., Testa L., Tolaney S. M., Huober J., et al.
ONCOLOGY RESEARCH AND TREATMENT , cilt.47, ss.8-9, 2024 (SCI-Expanded, Scopus) identifier

10. General Principles of Immunotherapy for Solid Tumors

ÖZCAN E., ÇİÇİN İ.
CURRENT IMMUNOTHERAPY LANDSCAPE FOR SOLID TUMORS , ss.1-4, 2024 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

11. Pilomatrix Carcinoma with Pulmonary Metastasis

AKGÜL F., CAN N., TOPUZ C., GÖKMEN İ., ÖZCAN E., HACIOĞLU M. B., et al.
Journal of Oncological Science , cilt.10, sa.1, ss.69-72, 2024 (Scopus, TRDizin) identifier

12. Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

Cho B. C., Lee J. S., Wu Y., ÇİÇİN İ., Dols M. C., Ahn M., et al.
Journal of Thoracic Oncology , cilt.18, sa.12, ss.1731-1742, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

13. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Karacin C., Oksuzoglu B., Demirci A., Keskinkılıç M., Baytemür N. K., Yılmaz F., et al.
BMC Cancer , cilt.23, sa.1, 2023 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

14. Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis

Soo R. A., Cho B. C., Kim J., Ahn M., Lee K. H., Zimina A., et al.
Journal of Thoracic Oncology , cilt.18, sa.12, ss.1756-1766, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

15. Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

AYDIN S., Kavak E. E., Topcu A., Bayramgil A., AKGÜL F., Kahraman S., et al.
Biomolecules and Biomedicine , cilt.23, sa.6, ss.1089-1095, 2023 (Scopus) Creative Commons License identifier identifier identifier

16. Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?

Guner G., AKTAŞ B. Y., Basal F. B., DEMİRKAZIK A., GÜRSOY P., Demirci U., et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , cilt.149, sa.14, ss.13271-13277, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

17. Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non-small cell lung cancer: A randomized, double-blind, phase III study

Chen L., Rangel J. D. G., Cil T., Li X., ÇİÇİN İ., Shen Y., et al.
CANCER MEDICINE , cilt.12, sa.22, ss.20847-20863, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

18. Coexistence of Anti-PD1-Induced Immune Myocarditis and Complete Atrioventricular Block: A Case Report

Gürdoğan M., Yalta K., Gürlertop Y., Karahan F., Bulburu İ. B., Koçyiğit B., et al.
AMERICAN JOURNAL OF CARDIOLOGY , cilt.207, ss.35-38, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

19. PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score

BAYOĞLU İ. V., Hüseynov J., TOPAL A., Sever N., Majidova N., Çelebi A., et al.
Journal of Clinical Medicine , cilt.12, sa.19, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

20. Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer

Gökmen İ., TAŞTEKİN E., Demir N., Özcan E., Akgül F., HACIOĞLU M. B., et al.
Current Issues in Molecular Biology , cilt.45, sa.10, ss.7803-7812, 2023 (SCI-Expanded, Scopus) identifier identifier identifier identifier

21. Lazertinib Versus Gefitinib as First-Line Treatment in Patients with EGFR -Mutated Advanced Non-Small-Cell Lung Cancer: Results from LASER301

Cho B. C., Ahn M., Kang J. H., Soo R. A., Reungwetwattana T., Yang J. C., et al.
Journal of Clinical Oncology , cilt.41, sa.26, ss.4208-4217, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

22. First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

ÖZGÜROĞLU M., Kilickap S., Sezer A., Gümüş M., Bondarenko I., Gogishvili M., et al.
The Lancet Oncology , cilt.24, sa.9, ss.989-1001, 2023 (SCI-Expanded, Scopus) identifier identifier identifier identifier

23. Classifying invasive lobular carcinoma as special type breast cancer may be reducing its treatment success: A comparison of survival among invasive lobular carcinoma, invasive ductal carcinoma, and no-lobular special type breast cancer

Coşar R., Süt N., Topaloğlu S., Taştekin E., Nurlu D., Özler T., et al.
PLoS ONE , cilt.18, sa.7 July, 2023 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

24. Major and minor salivary gland cancers: A multicenter retrospective study

HACIOĞLU M. B., ERDOĞAN B., Bardakcı M., Algın E., Gulbagcı B., Hacibekiroglu I., et al.
Head and Neck , cilt.45, sa.7, ss.1643-1653, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

25. Relationship between prognostic nutritional index and neutrophil lymphocyte ratio with overall survival in patients with metastatic colorectal cancer receiving regorafenib

ERDOĞAN B., Ozcan E., Gokmen I., Gokyer A., KÜÇÜKARDA A., KÖSTEK O., et al.
Journal of Cancer Research and Therapeutics , cilt.19, sa.3, ss.762-767, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

26. Patient preferences for use of archived biospecimens in Turkey.

KUBİLAY TOLUNAY P., Erol C., Kahraman S., Tacar S. Y., ÖZCAN E., Basal F. B., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.41, sa.16_SUPPL, 2023 (SCI-Expanded, Scopus) identifier

27. Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA plus CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study.

Siefker-Radtke A. O., Powles T., Moreno V., Kang T. W., Cicin I., Girvin A., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.41, sa.16_SUPPL, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

28. Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

BİLİCİ A., Olmez O. F., Kaplan M. A., Oksuzoglu B., Sezer A., Karadurmus N., et al.
ACTA ONCOLOGICA , cilt.62, sa.4, ss.381-390, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

29. Cancer-related hypercalcemia and potential treatments

Almuradova E., ÇİÇİN İ.
FRONTIERS IN ENDOCRINOLOGY , cilt.14, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier

30. External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

YEKEDÜZ E., Karakaya S., Ertürk İ., Tural D., Uçar G., Şentürk Öztaş N., et al.
Clinical Genitourinary Cancer , cilt.21, sa.1, ss.175-182, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

31. Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non–small cell lung cancer with PD-L1 of ≥50%: The EMPOWER-Lung 1 study

Gümüş M., Chen C., Ivanescu C., Kilickap S., Bondarenko I., ÖZGÜROĞLU M., et al.
Cancer , cilt.129, sa.1, ss.118-129, 2023 (SCI-Expanded, Scopus) identifier identifier identifier

32. Comparison of Extrapulmonary Small Cell Carcinoma and Small Cell Lung Carcinoma: A Single-Center Study

ÖZCAN E., KÜÇÜKARDA A., GÖKYER A., Sayin S., GÖKMEN İ., HACIOĞLU M. B., et al.
Journal of Oncological Science , cilt.9, sa.3, ss.134-141, 2023 (Scopus, TRDizin) identifier

33. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

Johnston S. R. D., Toi M., O'Shaughnessy J., Rastogi P., Campone M., Neven P., et al.
LANCET ONCOLOGY , cilt.24, sa.1, ss.77-90, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier identifier

34. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer

Paluch-Shimon S., Neven P., Huober J., ÇİÇİN İ., Goetz M. P. P., Shimizu C., et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY , cilt.15, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

35. An experimental study: the effect of S. boulardii on abemaciclib-induced diarrhea

CAKCAK İ. E., AYTİN Y. E., Sayin S., KÜÇÜKARDA A., GÖKYER A., GÖKMEN İ., et al.
Turkish Journal of Medical Sciences , cilt.53, sa.1, 2023 (SCI-Expanded, Scopus, TRDizin) Creative Commons License identifier identifier identifier

36. ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences

ÇİÇİN İ., Martin C., Haddad C. K., Kim S., Smolin A., Abdillah A., et al.
Critical Reviews in Oncology/Hematology , cilt.180, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

37. Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry

Bjartell A., Costa L., Kramer G., Zurawski B., Galli L., Werbrouck P., et al.
European Urology Open Science , cilt.45, ss.12-22, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

38. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study

Dogan I., Ayhan M., GÜRBÜZ M., KÜÇÜKARDA A., AYDIN E., ÜRÜN Y., et al.
MEDICINE , cilt.101, sa.35, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

39. Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey

ÖZET A., Dane F., Aykan N. F., Yalçln Ş., EVRENSEL T., ÖZKAN M., et al.
Future Oncology , cilt.18, sa.29, ss.3267-3276, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

40. El índice nutricional pronóstico como factor pronóstico independiente para la respuesta al tratamiento, la supervivencia y la elección del fármaco en el cáncer de próstata metastásico resistente a la castración tratado con acetato de abiraterona o enzalutamida

KÜÇÜKARDA A., GÖKYER A., Gökmen İ., ÖZCAN E., HACIOĞLU M. B., ERDOĞAN B., et al.
ACTAS UROLÓGICAS ESPAÑOLAS , cilt.46, ss.301-309, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

41. Prognostic nutritional index is an independent prognostic factor for treatment response, survival and drug choice in metastatic castration-resistant prostate cancer treated with abiraterone acetate or enzalutamide

KÜÇÜKARDA A., GÖKYER A., Gökmen İ., ÖZCAN E., HACIOĞLU M. B., ERDOĞAN B., et al.
Elsevier BV , cilt.46, sa.5, ss.301-309, 2022 (Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

42. Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)

Shitara K., Doi T., Hosaka H., Thuss-Patience P., Santoro A., Longo F., et al.
Gastric Cancer , cilt.25, sa.3, ss.586-597, 2022 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

43. Recurrent delayed immune-related pneumonitis after immune-checkpoint inhibitor therapy for advanced osteosarcoma

KÜÇÜKARDA A., GÖKMEN İ., ÖZCAN E., Peker P., AKGÜL F., ÇİÇİN İ.
Immunotherapy , cilt.14, sa.6, ss.395-399, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

44. Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade

Kelley R. K., Miksad R., ÇİÇİN İ., Chen Y., Klümpen H., Kim S., et al.
British Journal of Cancer , cilt.126, sa.4, ss.569-575, 2022 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

45. Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies

Shah M. A., Udrea A. A., Bondarenko I., Mansoor W., Sánchez R. G., Sarosiek T., et al.
Cancers , cilt.14, sa.5, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

46. Prognostic nutritional index and its dynamics after curative treatment are independent prognostic factors on survival in non-metastatic nasopharyngeal carcinoma

KÜÇÜKARDA A., ERDOĞAN B., Gökyer A., Sayın S., Gökmen İ., Özcan E., et al.
Supportive Care in Cancer , cilt.30, sa.3, ss.2131-2139, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

47. An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction

ÇİÇİN İ., Oukkal M., Mahfouf H., Mezlini A., Larbaoui B., Ben Ahmed S., et al.
European Journal of Breast Health , cilt.18, sa.1, ss.63-73, 2022 (Scopus, TRDizin) identifier identifier identifier

48. Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series

COŞAR R., SÜT N., Ozen A., TAŞTEKİN E., TOPALOĞLU S., ÇİÇİN İ., et al.
Breast Cancer: Targets and Therapy , cilt.14, ss.259-280, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

49. Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database

YEKEDÜZ E., Ertürk I., Tural D., Karadurmuş N., Karakaya S., Hlzal M., et al.
Future Oncology , cilt.17, sa.35, ss.4861-4869, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

50. Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective

Cicin I., ÇİÇİN İ., Oksuz E., Oksuz E., Karadurmus N., Karadurmus N., et al.
Health Economics Review , cilt.11, sa.1, 2021 (SSCI, Scopus) Creative Commons License identifier identifier identifier

51. A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer

Byers L. A., Navarro A., Schaefer E., Johnson M., ÖZGÜROĞLU M., Han J., et al.
Clinical Lung Cancer , cilt.22, sa.6, ss.531-540, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

52. Breast, ovarian and other site cancer patients with BRCA 1/2 mutations: Data from Turkish multicenter retrospective study

KÖSTEK O., KÜÇÜKARDA A., Tozkir H., Nihat Okten I., Ozden E., ÇABUK D., et al.
Journal of B.U.ON. , cilt.26, sa.6, ss.2654-2661, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

53. Ensartinib vs Crizotinib for Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Randomized Clinical Trial

Horn L., Wang Z., Wu G., Poddubskaya E., Mok T., Reck M., et al.
JAMA Oncology , cilt.7, sa.11, ss.1617-1625, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

54. Investigation of the relationship between GSTM1 gene variations and serum trace elements, plasma malondialdehyde levels in patients with colorectal cancer

AY A., GÜLYAŞAR T., Alkanli N., SİPAHİ T., ÇİÇİN İ., KOÇAK Z., et al.
Molecular Biology Reports , cilt.48, sa.10, ss.6911-6921, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

55. Tyrosine kinase inhibitors in the treatment of metastatic renal cell cancer patients with early cytokine intolerance: TURCOS, a Turkish national, prospective observational study

Benekli M., Gumus M., ÖZKAN M., Dane F., ELKIRAN E. T., ÇİÇİN İ., et al.
Journal of Oncology Pharmacy Practice , cilt.27, sa.7, ss.1623-1630, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

56. Merkel cell carcinoma in Turkey: A multicentric study

Yildiz F., Demirci U., KÜÇÜKARDA A., BÜYÜKŞİMŞEK M., Sakalar T., Topcu T. O., et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS , cilt.17, sa.6, ss.1525-1529, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

57. Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?

ERDOĞAN B., KÖSTEK O., HACIOĞLU M. B., GÖKYER A., KÜÇÜKARDA A., ÖZCAN E., et al.
Journal of B.U.ON. , cilt.26, sa.5, ss.2196-2201, 2021 (SCI-Expanded, Scopus) identifier identifier

58. Enzalutamide versus Abiraterone Acetate as first-line treatment of castration resistant metastatic prostate cancer in geriatric (≥75) patients

Alkan A., Guc Z. G., GÜRBÜZ M., ozgun G., Degirmencioglu S., Dogan M., et al.
JOURNAL OF MENS HEALTH , cilt.17, sa.4, ss.128-134, 2021 (SCI-Expanded, SSCI, Scopus) Sürdürülebilir Kalkınma identifier identifier

59. Pembrolizumab plus Ipilimumab or Placebo for Metastatic Non–Small-Cell Lung Cancer with PDL1 Tumor Proportion Score ‡ 50%: Randomized, Double-Blind Phase III KEYNOTE-598 Study

Boyer M., ŞENDUR M. A. N., Rodríguez-Abreu D., Park K., Lee D. H., ÇİÇİN İ., et al.
Journal of Clinical Oncology , cilt.39, sa.21, ss.2327-2338, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

60. Real-life data on first-line sunitinib and pazopanib therapy in metastatic renal cell carcinoma patients: A single center experience

TOPAL A., Sayın S., GÖKYER A., KÜÇÜKARDA A., KÖSTEK O., HACIOĞLU M. B., et al.
Journal of B.U.ON. , cilt.26, sa.4, ss.1628-1634, 2021 (SCI-Expanded, Scopus) identifier identifier

61. Nasal hemangiopericytoma presenting with oncogenic osteomalasia: A case report and literature review

Gökyer A., Sayın S., KÜÇÜKARDA A., ÇELİK M., Güldiken S., Çiçin İ.
Current Problems in Cancer , cilt.45, sa.3, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

62. Secondary pneumothorax during immunotherapy in two patients with metastatic solid tumors; a new entity

KÜÇÜKARDA A., Sayin S., GÖKYER A., Aykan M. B., Karadurmus N., ÇİÇİN İ.
IMMUNOTHERAPY , cilt.13, sa.7, ss.565-570, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

63. Skeletal muscle loss during anti-epidermal growth factor receptor therapy is an independent prognostic factor on non-small cell lung cancer patients survival

KÜÇÜKARDA A., GÖKYER A., GÖKMEN İ., Bekir Hacioglu M., KÖSTEK O., KURT N., et al.
Journal of B.U.ON. , cilt.26, sa.3, ss.853-860, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

64. The relation between tissue galectin-3 level and platinum resistance in neoadjuvant bladder cancer treatment

Gokyer A., KÜÇÜKARDA A., KÖSTEK O., Sayin S., CAN N., HACIOĞLU M. B., et al.
Journal of B.U.ON. , cilt.26, sa.3, ss.1034-1039, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

65. Investigation of the relationship of TNFRSF11A gene polymorphisms with breast cancer development and metastasis risk in patients with BRCA1 or BRCA2 pathogenic variants living in the Trakya region of Turkey

Özdemir K., Gürkan M. P., DEMİR S., ATLI E. İ., ÖZEN Y., SEZER Y. A., et al.
Balkan Journal of Medical Genetics , cilt.23, sa.2, ss.49-58, 2021 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

66. Metastatic cutaneous melanoma epidemiological registry in Turkey: A preliminary evaluation of diagnosis and treatment approaches

Karaca B. S., Sezer A., SEZGİN GÖKSU S., ÇİÇİN İ., Erdem D., ÇUBUKÇU E., et al.
JOURNAL OF TRANSLATIONAL MEDICINE , cilt.19, sa.SUPPL 1, 2021 (SCI-Expanded, Scopus) identifier

67. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Sezer A., Kilickap S., Gümüş M., Bondarenko I., ÖZGÜROĞLU M., Gogishvili M., et al.
The Lancet , cilt.397, sa.10274, ss.592-604, 2021 (SCI-Expanded, Scopus) identifier identifier identifier identifier

68. Need for patient education and better physician-patient communication in melanoma patients: Behaviors and knowledge of melanoma patients Melanom hastalarının melanom hakkında eğitim ve daha iyi hasta-hekim iletişimi ihtiyacı

Solak S. S., YÖNDEM H., Çiçin I.
Turkderm Turkish Archives of Dermatology and Venereology , cilt.55, sa.1, ss.27-33, 2021 (ESCI, Scopus, TRDizin) Creative Commons License identifier identifier identifier

69. Clinicopathological and prognostic characteristics of acral metastases in patients with malignant disease: A retrospective study

ÇİFTDEMİR M., USTABAŞIOĞLU F. E., ÇÖLBE S. A., ÜSTÜN F., USTA U., ÇİÇİN İ.
Acta Orthopaedica et Traumatologica Turcica , cilt.55, sa.1, ss.67-72, 2021 (SCI-Expanded, Scopus, TRDizin) Creative Commons License identifier identifier identifier identifier

70. Distribution data of epidermal growth factor receptor mutations detected by next-generation sequencing method in non-small cell lung cancer

GÖKMEN İ., TAŞTEKİN E., GÖKYER A., Sayin S., ÇİÇİN İ.
Journal of Oncological Science , cilt.7, sa.2, ss.77-80, 2021 (Scopus, TRDizin) identifier

71. Third-line Therapy for Metastatic Renal Cell Carcinoma and Its Effect on Quality of Life and Overall Survival: A National, Multicenter, Observational Study

Çiçin I., ÇİLTAŞ A., Kılıçkap S., oksuzoglu b., UNCU D., Artac M., et al.
Journal of oncological sciences , cilt.6, sa.2, ss.87-95, 2020 (Scopus, TRDizin) identifier

72. Optimal Cytoreduction is an Independent Prognostic Factor in Ovarian Carcinosarcoma: A Turkish Gynecologic Oncology Group Study

Ayhan A., Çiçin I., Gökyer A., Sarı M. E., Turan T., Taşkın S., et al.
Journal of oncological sciences , cilt.6, sa.2, ss.78-86, 2020 (Scopus, TRDizin) identifier

73. Targeted next-generation sequencing as a diagnostic tool in gastrointestinal system cancer/polyposis patients

YALÇINTEPE S., GÜRKAN H., DEMİR S., TOZKIR H., TEZEL H. A., ATLI E. İ., et al.
Tumori , cilt.106, sa.6, ss.510-517, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

74. Stage I colon cancer that spreads into a colovesical fistula-mediated bladder due to crohn’s disease: A case report

GÖKYER A., KÜÇÜKARDA A., SAYIN S., KESKİN F. E. U., ÇİÇİN İ.
CURRENT PROBLEMS IN CANCER: CASE REPORTS , cilt.1, sa.1, ss.10-12, 2020 (Scopus) Sürdürülebilir Kalkınma identifier

75. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE)

Johnston S. R., Harbeck N., Hegg R., Toi M., Martin M., Shao Z. M., et al.
Journal of Clinical Oncology , cilt.38, sa.34, ss.3987-3998, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

76. Evaluating sun protection behaviors and skin self-examination practices among the family members of melanoma patients in Turkey: A cross-sectional survey study

SARIKAYA SOLAK S., YÖNDEM H., ÇİÇİN İ.
Dermatologic Therapy , cilt.33, sa.6, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

77. A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous NSCLC: Protocol-Specified Final Analysis of KEYNOTE-407

Paz-Ares L., Vicente D., Tafreshi A., Robinson A., Soto Parra H., Mazières J., et al.
Journal of Thoracic Oncology , cilt.15, sa.10, ss.1657-1669, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

78. Contrast nephropathy in cancer patients receiving anti-VEGF therapy: a prospective study

Gökyer A., KÜÇÜKARDA A., KÖSTEK O., HACIOĞLU M. B., Uzunoğlu S., KULA O., et al.
International Journal of Clinical Oncology , cilt.25, sa.10, ss.1757-1762, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

79. Neutrophil–lymphocyte ratio as a prognostic factor for survival in patients with advanced renal cell carcinoma (Turkish Oncology Group Study)

Hizal M., Sendur M. A., YAŞAR H. A., Bir Yucel K., Arslan C., Ucar G., et al.
Journal of Oncology Pharmacy Practice , cilt.26, sa.7, ss.1583-1589, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

80. GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Peled N., Gillis R., Kilickap S., Froesch P., Orlov S., Filippova E., et al.
Lung Cancer , cilt.148, ss.48-54, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

81. Efficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkey

HACIOĞLU M. B., KÖSTEK O., KARABULUT S., TAŞTEKİN D., SEZGİN GÖKSU S., Alandag C., et al.
Journal of B.U.ON. , cilt.25, sa.4, ss.1897-1903, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

82. The relationship between prognostic nutritional index and treatment response in patients with metastatic renal cell cancer

YAŞAR H. A., Bir Yucel K., Arslan C., Ucar G., Karakaya S., Bilgin B., et al.
Journal of Oncology Pharmacy Practice , cilt.26, sa.5, ss.1110-1116, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

83. Genetic screening results of individuals with high risk BRCA-related breast/ovarian cancer in Trakya region of Turkey

DEMİR S., Tozkir H., GÜRKAN H., Ikbal Atli E., YALÇINTEPE S., ATLI E., et al.
Journal of B.U.ON. , cilt.25, sa.3, ss.1337-1347, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

84. Immunotherapy in Elderly Cancer Patients

GÖKYER A., KÜÇÜKARDA A., ÇİÇİN İ.
TIBBI ONKOLOJI - GERIATRIK ONKOLOJI , cilt.22, ss.555-562, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier identifier

85. Relationship between the size and location of the mass and hilar and mediastinal lymph node metastasis in early and locally advanced non-small cell lung cancer

Kuzucuoglu M., GÖKYER A., KULA O., YEKDEŞ A. C., SUNAL B. S., KARAMUSTAFAOĞLU Y. A., et al.
Journal of the College of Physicians and Surgeons Pakistan , cilt.30, sa.2, ss.172-176, 2020 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

86. Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer

Mazieres J., Kowalski D., Luft A., Vicente D., Tafreshi A., Gümüş M., et al.
Journal of Clinical Oncology , cilt.38, sa.3, ss.271-280, 2020 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

87. Concordance of PD-l1 expression and CD8+ til intensity between nsclc and synchronous brain metastases

BATUR Ş., Dulger O., Durak S., Yumuk P. F., Caglar H. B., BOZKURTLAR E., et al.
Bosnian Journal of Basic Medical Sciences , cilt.20, sa.3, ss.329-335, 2020 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

88. The relationship between fdg PET/CT-defined metabolic parameters and the histopathological subtype of oesophageal carcinomas

KORKMAZ KARA Ü., HACIOĞLU M. B., KÖSTEK O., SÜT N., Kodaz H., ERDOĞAN B., et al.
Polish Journal of Radiology , cilt.85, sa.1, 2020 (ESCI, Scopus) Creative Commons License identifier identifier identifier

89. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial

Petrylak D. P., de Wit R., Chi K. N., Drakaki A., Sternberg C. N., Nishiyama H., et al.
The Lancet Oncology , cilt.21, sa.1, ss.105-120, 2020 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier identifier

90. Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study

Bachet J., Wyrwicz L., Price T., Cremolini C., Phelip J., Portales F., et al.
ESMO Open , cilt.5, sa.3, ss.1-10, 2020 (SCI-Expanded, Scopus) identifier identifier identifier

91. Relation between sarcopenia and dose-limiting toxicity in patients with metastatic colorectal cancer who received regorafenib

GÖKYER A., KÜÇÜKARDA A., KÖSTEK O., HACIOĞLU M. B., Sunal B., Demircan N., et al.
Clinical and Translational Oncology , cilt.21, sa.11, ss.1518-1523, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

92. Aflibercept Plus FOLFIRI for Second-line Treatment of Metastatic Colorectal Cancer: Observations from the Global Aflibercept Safety and Health-Related Quality-of-Life Program (ASQoP)

Riechelmann R. P., Srimuninnimit V., Bordonaro R., Kavan P., Di Bartolomeo M., Maiello E., et al.
Clinical Colorectal Cancer , cilt.18, sa.3, ss.183, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

93. Prognostic factors and oncological outcomes of ovarian yolk sac tumors: a retrospective multicentric analysis of 99 cases

Boyraz G., Durmus Y., ÇİÇİN İ., KURU O., LEVENTOĞLU Ö. S., Comert G. K., et al.
Archives of Gynecology and Obstetrics , cilt.300, sa.1, ss.175-182, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

94. Changes in skeletal muscle area and lean body mass during pazopanib vs sunitinib therapy for metastatic renal cancer

KÖSTEK O., Yılmaz E., HACIOĞLU M. B., Demircan N. C., Gökyer A., Uzunoğlu S., et al.
Cancer Chemotherapy and Pharmacology , cilt.83, sa.4, ss.735-742, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

95. Effect of clinical and pathological features of gastrointestinal stromal tumors on overall survival and prognosis: Single center experience

MEREV E., Çiçin I.
Journal of oncological sciences , cilt.5, sa.3, ss.73-79, 2019 (Scopus, TRDizin) identifier

96. Regorafenib or rechallenge chemotherapy: which is more effective in the third-line treatment of metastatic colorectal cancer?

KÖSTEK O., Hacıoğlu M. B., Sakin A., Demir T., Sarı M., Ozkul O., et al.
Cancer Chemotherapy and Pharmacology , cilt.83, sa.1, ss.115-122, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

97. Pertuzumab, trastuzumab and taxane-based treatment for visceral organ metastatic, trastuzumab-naïve breast cancer: real-life practice outcomes

Esin E., Oksuzoglu B., BİLİCİ A., ÇİÇİN İ., KÖSTEK O., Kaplan M., et al.
Cancer Chemotherapy and Pharmacology , cilt.83, sa.1, ss.131-143, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

98. Is the Charlson comorbidity index a prognostic indicator for toxicity and mortality in elderly patients with locally advanced rectal cancer?

KÖSTEK O., Bozkaya Y., HACIOĞLU M. B., Özdemir N. Y., YILMAZ E., Demircan N. C., et al.
Archives of Iranian Medicine , cilt.22, sa.5, ss.236-241, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

99. Comparison of skeletal muscle mass loss in patients with metastatic colorectal cancer treated with regorafenib or TAS-102

HACIOĞLU M. B., KÖSTEK O., Kurt N., KÜÇÜKARDA A., Gokyer A., USTABAŞIOĞLU F. E., et al.
Journal of B.U.ON. , cilt.24, sa.5, ss.2198-2204, 2019 (SCI-Expanded, Scopus) identifier identifier identifier

100. Effectiveness and Safety of LMWH Treatment in Patients With Cancer Diagnosed With Non-High-Risk Venous Thromboembolism: Turkish Observational Study (TREBECA)

Ozaslan E., ÖZKAN M., ÇİÇİN İ., Benekli M., KOÇER M., Uysal M., et al.
Clinical and Applied Thrombosis/Hemostasis , cilt.24, sa.6, ss.973-979, 2018 (SCI-Expanded, Scopus) identifier identifier identifier

101. A retrospective study on potential drug interactions: A single center experience

Korucu F. C., Şenyiğit E., KÖSTEK O., ERDOĞAN B., UZUNOĞLU S., ÇİÇİN İ.
Journal of Oncological Sciences , cilt.4, sa.2, ss.80-84, 2018 (Hakemli Dergi)

102. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma

Abou-Alfa G. K., Meyer T., Cheng A., El-Khoueiry A. B., Rimassa L., Ryoo B., et al.
New England Journal of Medicine , cilt.379, sa.1, ss.54-63, 2018 (SCI-Expanded, Scopus) identifier identifier identifier

103. Value of MRI apparent diffusion coefficient for assessment of response to sorafenib in hepatocellular carcinoma

KÖSTEK O., YILMAZ E., HACIOĞLU M. B., ERDOĞAN B., Kodaz H., Bekmez E. T., et al.
Journal of B.U.ON. , cilt.23, sa.4, ss.979-984, 2018 (SCI-Expanded, Scopus) identifier identifier identifier

104. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase 3 CELESTIAL trial.

Abou-Alfa G. K., Meyer T., Cheng A., El-Khoueiry A., Rimassa L., Ryoo B., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.36, sa.15, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

105. Outcomes based on age in the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC).

Rimassa L., Cicin I., Blanc J., Klumpen H. J., Zagonel V., Tran A., et al.
JOURNAL OF CLINICAL ONCOLOGY , cilt.36, sa.15, 2018 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier

106. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial

Petrylak D., de Wit R., Chi K. N., Drakaki A., Sternberg C. N., Nishiyama H., et al.
The Lancet , cilt.390, sa.10109, ss.2266-2277, 2017 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier identifier

107. Assessment of prognostic factors in epithelial ovarian cancer

ÖNAL Y., KÖSTEK O., HACIOĞLU M. B., ERDOĞAN B., KODAZ H., TÜRKMEN BEKMEZ E., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , cilt.1, sa.2, ss.61-68, 2017 (Hakemli Dergi) identifier

108. A Rare Cause of Acute Kidney Injury: Renal ArterialThrombosis in a Small Cell Lung Cancer Patient

KÖSTEK O., HACIOĞLU M. B., ORMAN S., ÇETİN C., KODAL N. S., ERDOĞAN B., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , cilt.1, sa.1, ss.41-43, 2017 (Hakemli Dergi) identifier

109. Combination of Docetaxel and Gemcitabine Ineffective in Metastatic Eccrine Porocarcinoma: A Case Report

KODAZ H., HACIOĞLU M. B., KÖSTEK O., ERDOĞAN B., TAŞTEKİN E., KODAZ ELPEN Ç., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , cilt.1, sa.1, ss.38-40, 2017 (Hakemli Dergi) identifier

110. Frequency of RAS Mutations (KRAS, NRAS, HRAS) in Human Solid Cancer

KODAZ H., KÖSTEK O., HACIOĞLU M. B., ERDOĞAN B., KODAZ ELPEN Ç., HACIBEKİROĞLU İ., et al.
EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY , cilt.1, sa.1, ss.1-7, 2017 (Hakemli Dergi) Sürdürülebilir Kalkınma identifier

111. Targeted therapy with anaplastic lymphoma kinase inhibitors in non-small cell lung cancer even with brain metastasis

Hacioglu B. M., KÖSTEK O., ERDOĞAN B., Uzunoglu S., ÇİÇİN İ.
Journal of B.U.ON. , cilt.22, sa.3, ss.586-591, 2017 (SCI-Expanded, Scopus) identifier identifier identifier

112. Clinical Features of the Patient with Multiple Primary Tumors: Single Center Experience

GÖKYER A., KÖSTEK O., HACIOĞLU M. B., ERDOĞAN B., KODAZ H., TÜRKMEN E., et al.
NORTHERN CLINICS OF ISTANBUL = ISTANBUL KUZEY KLINIKLERI , cilt.4, sa.1, ss.43-51, 2017 (TRDizin) identifier identifier

113. K-RAS and N-RAS mutations in testicular germ cell tumors

Hacioglu B. M., Kodaz H., ERDOĞAN B., Cinkaya A., TAŞTEKİN E., Hacibekiroglu I., et al.
Bosnian Journal of Basic Medical Sciences , cilt.17, sa.2, ss.159-163, 2017 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

114. Unknown primary adenocarcinomas: A single-center experience

Uzunoglu S., ERDOĞAN B., KODAZ H., Cinkaya A., Turkmen E., Hacibekiroglu I., et al.
Bosnian Journal of Basic Medical Sciences , cilt.16, sa.4, ss.292-297, 2016 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

115. Impact of active smoking on survival of patients with metastatic lung adenocarcinoma harboring an epidermal growth factor receptor (EGFR) mutation

ERDOĞAN B., KODAZ H., Karabulut S., Cinkaya A., TOZKIR H., Tanriverdi O., et al.
Bosnian Journal of Basic Medical Sciences , cilt.16, sa.4, ss.280-285, 2016 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

116. Predictive and prognostic factors in ovarian and uterine carcinosarcomas

Cicin İ., Özatlı T., Türkmen E., Özturk T., Özçelik M., ÇABUK D., et al.
Balkan Medical Journal , cilt.33, sa.5, ss.517-524, 2016 (SCI-Expanded, Scopus, TRDizin) identifier identifier identifier identifier

117. Durable response with medroxiprogesterone acetate in metastatic renal cell carcinoma: Case report

HACIOĞLU M. B., KÖSTEK O., ERDOĞAN B., KODAZ H., HACIBEKİROĞLU İ., TÜRKMEN E., et al.
Journal of Oncological Sciences , cilt.2, sa.2-3, ss.69-70, 2016 (Hakemli Dergi)

118. KRAS mutation in small cell lung carcinoma and extrapulmonary small cell cancer

KODAZ H., TAŞTEKİN E., ERDOĞAN B., Hacıbekiroğlu İ., TOZKIR H., GÜRKAN H., et al.
Balkan Medical Journal , cilt.33, sa.4, ss.407-410, 2016 (SCI-Expanded, Scopus, TRDizin) identifier identifier identifier identifier

119. Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment

Turkmen E., ERDOĞAN B., KODAZ H., Hacibekiroglu I., ÖNAL Y., Uzunoglu S., et al.
Acta Gastro-Enterologica Belgica , cilt.79, sa.2, ss.211-215, 2016 (Scopus) identifier identifier identifier

120. Endometrial carcinoma and paraneoplastic immune thrombocytopenia

KODAZ H., HACIOĞLU M. B., ELPEN KODAZ Ç., ÇİNKAYA A., ERDOĞAN B., ÇİÇİN İ.
Journal of Oncological Science , cilt.2, sa.1, ss.25-26, 2016 (Hakemli Dergi)

121. The effect of the gastrectomy on survival in patients with metastatic gastric cancer: a study of ASMO

Yazici O., ÖZDEMİR N., Duran A. O., Menekse S., Ali M., Sendur N., et al.
FUTURE ONCOLOGY , cilt.12, sa.3, ss.343-354, 2016 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

122. Potential problems of biosimilars in clinical practice Biyobenzer ürünlerde klinik uygulamada karşılaşılabilecek sorunlar

Korucu F. C., NAZLI H., GEDİK G., ÇİÇİN İ.
Marmara Pharmaceutical Journal , cilt.20, sa.1, ss.44-51, 2016 (Scopus, TRDizin) Creative Commons License identifier identifier

123. A rare cause in etiology of left atrial mass: Metastatic testicular germ cell tumor

Huseyin S., YÜKSEL V., OKYAY A., Hacibekiroǧlu I., TAŞTEKİN E., Yilmaztepe M., et al.
Kardiochirurgia i Torakochirurgia Polska , cilt.13, sa.1, ss.45-48, 2016 (Scopus) Creative Commons License identifier identifier identifier

124. Comparative analysis of the efficacy and safety of modified FOLFOX 6 and DCF regimens as first line treatment in advanced gastric cancer

HACIBEKİROĞLU İ., KODAZ H., ERDOĞAN B., TÜRKMEN E., ESENKAYA A., ÖNAL Y., et al.
MOLECULAR AND CLINICAL ONCOLOGY , cilt.3, sa.5, ss.1160-1164, 2015 (Hakemli Dergi) identifier identifier

125. Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients.

KODAZ H., ERDOĞAN B., HACIBEKİROĞLU İ., TÜRKMEN E., TOZKIR H., ALBAYRAK D., et al.
HEPATO-GASTROENTEROLOGY , cilt.62, sa.140, ss.876-879, 2015 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier

126. Importance of Ki-67 in human epidermal growth factor receptor 2 positive breast cancer

ERDOĞAN B., Turkmen E., YALTA T. D., USTA U., KODAZ H., Hacibekiroglu I., et al.
Journal of B.U.ON. , cilt.20, sa.3, ss.730-736, 2015 (SCI-Expanded, Scopus) identifier identifier identifier

127. Single-agent bevacizumab is an effective treatment in recurrent glioblastoma

Hacibekiroglu I., KODAZ H., ERDOĞAN B., Turkmen E., Ozcelik M., ESENKAYA A., et al.
Medical Oncology , cilt.32, sa.2, 2015 (SCI-Expanded, Scopus) identifier identifier identifier

128. Denosumab - a monoclonal antibody, not a radionuclide

ERDOĞAN B., ÇİÇİN İ.
Asian Pacific Journal of Cancer Prevention , cilt.16, sa.5, ss.1, 2015 (Scopus) identifier identifier

129. Increased dose single-agent gemcitabine in platinum-taxane resistant metastatic ovarian cancer

KODAZ H., Hacibekiroglu I., Turkmen E., ERDOĞAN B., Elpen C., Uzunoglu S., et al.
Tumori , cilt.101, sa.1, ss.36-40, 2015 (SCI-Expanded, Scopus) identifier identifier identifier

130. Impact of bevacizumab on survival outcomes in primary tumor resected metastatic colorectal cancer

KODAZ H., ERDOĞAN B., Hacibekiroglu I., Turkmen E., GÜRKAN H., ALBAYRAK D., et al.
Medical Oncology , cilt.32, sa.1, ss.1-5, 2015 (SCI-Expanded, Scopus) identifier identifier identifier

131. Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors

KODAZ H., HACIBEKİROĞLU İ., ERDOĞAN B., TÜRKMEN E., TOZKIR H., ALBAYRAK D., et al.
MOLECULAR AND CLINICAL ONCOLOGY , cilt.3, sa.1, ss.179-184, 2014 (Hakemli Dergi) identifier identifier

132. Incidence of contrast-induced nephropathy in hospitalised patients with cancer

ÇİÇİN İ., ERDOĞAN B., GÜLŞEN E., Uzunoglu S., SÜT N., Turkmen E., et al.
European Radiology , cilt.24, sa.1, ss.184-190, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

133. Medical Treatment of Breast Cancer Bone Metastasis: From Bisphosphonates to Targeted Drugs

ERDOĞAN B., ÇİÇİN İ.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION , cilt.15, sa.4, ss.1503-1510, 2014 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier

134. A case of Guillain-Barre syndrome in a patient with small cell lung cancer treated with chemotherapy Tedavi esnasında Guillain-Barre sendromu gelişen küçük hücreli akciğer karsinomu olgusu

Türkmen E., ERDOĞAN B., Hacıbekiroğlu İ., KODAZ H., Uzunoğlu S., ÇELİK Y., et al.
Turk Onkoloji Dergisi , cilt.29, sa.3, ss.104-107, 2014 (Scopus) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

135. A rarely seen mucoepidermoid carcinoma of the left main bronchus

KUZUCUOĞLU M., Karamustafaoglu Y. A., ÇİÇİN İ., YÖRÜK Y.
Journal of Cancer Research and Therapeutics , cilt.10, sa.2, ss.384-386, 2014 (SCI-Expanded, Scopus) identifier identifier identifier

136. Carnitine or dimethyl sulfoxide, or both, for the treatment of anthracycline extravasation in rats

Uzunoglu S., COŞAR R., ÇİÇİN İ., İBİŞ K., Demiralay E., BENLİER E., et al.
Journal of Plastic Surgery and Hand Surgery , cilt.47, sa.5, ss.339-343, 2013 (SCI-Expanded, Scopus) identifier identifier identifier

137. Performance status is an important prognostic factor in second line treatment of pancreaticobiliary adenocarcinoma

ERDOĞAN B., Turkmen E., Uzunoglu S., Tanriverdi O., ÇİÇİN İ.
Hepato-Gastroenterology , cilt.60, sa.126, ss.1479-1483, 2013 (SCI-Expanded, Scopus) identifier identifier identifier

138. Assessment of CA-125 area under the curve as a prognostic factor in patients with ovarian cancer

Uzunoglu S., Aybatli A., Kaplan P. B., ÇİÇİN İ., SÜT N., Sayin C., et al.
Medical Oncology , cilt.30, sa.1, 2013 (SCI-Expanded, Scopus) identifier identifier identifier

139. Hypothermia in Hodgkin's disease: unexpected state; case report and rewiew of the literature

GÜNDOĞ M., ÇİÇİN İ., Ustun C.
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.28, sa.1, ss.41-43, 2013 (ESCI, Scopus) Sürdürülebilir Kalkınma identifier identifier

140. Protective effect of L-carnitine versus amifostine against cisplatin-induced nephrotoxicity in rats

Uzunoglu S., KARAGÖL H., Ozpuyan F., COŞAR R., ÇİÇİN İ., Yurutcaloglu V., et al.
MEDICAL ONCOLOGY , cilt.28, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

141. Breast Conserving Surgery and Sentinel Lymph Node Biopsy in Locally Advanced Breast Cancer: Single Center Experience

SEZER Y. A., Alas R., Cicin I., Hoşcoşkun Z., TUNÇBİLEK N.
BALKAN MEDICAL JOURNAL , cilt.28, sa.2, ss.138-142, 2011 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier

142. A RARE BREAST TUMOR: SECRETORY BREAST CARCINOMA

YAĞCI M. A., Sezer A., YELDAN E., HOŞCOŞKUN Z., Hatipoglu A., Altaner S., et al.
JOURNAL OF BREAST HEALTH , cilt.7, sa.2, ss.140-142, 2011 (ESCI) Sürdürülebilir Kalkınma identifier

143. KANSER HASTASINDA BESLENME

ERDOĞAN B., ÇİÇİN İ.
KLİNİK GELİŞİM , cilt.24, sa.3, ss.25-29, 2011 (Hakemsiz Dergi) Sürdürülebilir Kalkınma

144. Türkiye’de meme kanserli hastaların tanı ve tedavi yöntemlerine ulaşım hızı; çok merkezli gözlemsel çalışma

Saip P., Keskin S., Ozkan M., KAPLAN M. A., AYDOĞAN F., DEMİRAĞ G. G., et al.
Meme Sağlığı Dergisi , cilt.7, sa.2, ss.109-117, 2011 (TRDizin) identifier

145. A brief look at the evaluation of the development and effectiveness of cytotoxic chemotherapy in advanced non-small-cell lung cancer İleri evre küçük hücreli dişi akciǧer kanseri tedavisinde kemoterapinin son yillarda gelişim ve etkinliǧinin deǧerlendirilmesine kisa bir bakiş

Uzunoǧlu S., KARAGÖL H., Tanriverdi Ö., ÇİÇİN İ., Çaloǧlu M., KOÇAK Z.
Turk Onkoloji Dergisi , cilt.25, sa.2, ss.77-85, 2010 (Scopus) identifier

146. Hemodynamic instability due to intratumoral hemorrhage in retroperitoneal alveolar rhabdomyosarcoma in adult

SEZER Y. A., YAĞCI M. A., HATİPOĞLU A. R., COŞKUN İ., Calta F., ÇİÇİN İ., et al.
HealthMED , cilt.4, sa.3, ss.533-535, 2010 (SCI-Expanded, Scopus) identifier identifier

147. Inflammatory myofibroblastic tumor presenting as an abdominal wall mass in an adult patient

YAĞCI M. A., SEZER Y. A., YELDAN E., COŞKUN İ., USTA U., ÇİÇİN İ., et al.
Journal of Cancer Research and Therapeutics , cilt.6, sa.2, ss.224-226, 2010 (SCI-Expanded, Scopus) identifier identifier identifier

148. A brief look at the evaluation of the development and effectiveness of cytotoxic chemotherapy in advanced non-small-cell lung cancer

Uzunoglu S., KARAGÖL H., Tanriverdi O., ÇİÇİN İ., ÇALOĞLU H. M., KOÇAK Z.
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.25, sa.2, ss.77-85, 2010 (ESCI, Scopus) Sürdürülebilir Kalkınma identifier

149. A destroyer immunologic cause in small cell lung carcinoma: Ectopic Cushing's syndrome Küçük hücreli akciǧer kanserinde yıkıcı bir durum: Ektopik Cushing sendromu

ÇİÇİN İ., Uzunoǧlu S., ERMANTAŞ N., USTA U., TEMİZÖZ O., KARAGÖL H.
Trakya Universitesi Tip Fakultesi Dergisi , cilt.27, sa.3, ss.312-314, 2010 (SCI-Expanded, Scopus, TRDizin) Creative Commons License identifier identifier

150. A case of malignant melanoma with cardiac and gallbladder metastases detected by FDG PET-CT

Özülker T., Özülker F., ÇİÇİN İ., Özpaçac T.
Clinical Nuclear Medicine , cilt.34, sa.12, ss.948-949, 2009 (SCI-Expanded, Scopus) identifier identifier identifier

151. Extrapulmonary small cell carcinoma localized in lymph nodes: Is it a different clinical entity?

ÇİÇİN İ., USTA U., KARAGÖL H., Uzunoglu S., KOÇAK Z.
Acta Oncologica , cilt.48, sa.3, ss.354-360, 2009 (SCI-Expanded, Scopus) identifier identifier identifier

152. Pleomorphic liposarcoma of the pectoralis major muscle in an elderly man: Report of a case and review of literature

SEZER Y. A., TUNÇBİLEK N., USTA U., Cosar-Alas R., ÇİÇİN İ.
Journal of Cancer Research and Therapeutics , cilt.5, sa.4, ss.315-317, 2009 (Scopus) identifier identifier identifier

153. The effect of Saccharomyces boulardii on reducing irinotecan-induced intestinal mucositis and diarrhea

SEZER Y. A., USTA U., ÇİÇİN İ.
Medical Oncology , cilt.26, sa.3, ss.350-357, 2009 (SCI-Expanded, Scopus) identifier identifier identifier

154. Triple negative breast cancer compared to hormone receptor negative/HER2 positive breast cancer

ÇİÇİN İ., KARAGÖL H., USTA U., SEZER Y. A., Uzunoglu S., Alas-Cosar R., et al.
MEDICAL ONCOLOGY , cilt.26, sa.3, ss.335-343, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

155. The comparison of weekly and three-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic squamous cell carcinoma of the head and neck

UYGUN K., Bilici A., KARAGÖL H., Caloglu M., ÇİÇİN İ., AKSU M. G., et al.
Cancer Chemotherapy and Pharmacology , cilt.64, sa.3, ss.601-605, 2009 (SCI-Expanded, Scopus) identifier identifier identifier

156. Malignant ovarian germ cell tumors: A single-institution experience

ÇİÇİN İ., Eralp Y., Saip P., Ayan I., Kebudi R., Iyibozkurt C., et al.
American Journal of Clinical Oncology: Cancer Clinical Trials , cilt.32, sa.2, ss.191-196, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

157. Synchronous tonsil, gallbladder, and cardiac metastases without any other visceral metastases of malignant melanoma

ÇİÇİN İ., USTA U., SEZER Y. A., CANBAZ S., Uzunoglu S., KARAGÖL H., et al.
Onkologie , cilt.32, sa.4, ss.197-199, 2009 (SCI-Expanded, Scopus) identifier identifier identifier

158. Massive Upper Gastrointestinal Bleeding From Pure Metastatic Choriocarcinoma in Patient With Mixed Germ Cell Tumor With Subclinical Intestinal Metastasis

Cicin I., Ozyilmaz F., Karagol H., Yalcin F., Uzunoglu S., Kaplan M.
UROLOGY , cilt.73, sa.2, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

159. Yolk sac tumours of the ovary: Evaluation of clinicopathological features and prognostic factors

ÇİÇİN İ., Saip P., Guney N., Eralp Y., Ayan I., KEBUDİ R., et al.
European Journal of Obstetrics and Gynecology and Reproductive Biology , cilt.146, sa.2, ss.210-214, 2009 (SCI-Expanded, Scopus) identifier identifier identifier

160. Identification of patients who may benefit from the prophylactic cranial radiotherapy among breast cancer patients with brain metastasis

Saip P., ÇİÇİN İ., Eralp Y., KARAGÖL H., Kucucuk S., Cosar Alas R., et al.
Journal of Neuro-Oncology , cilt.93, sa.2, ss.243-251, 2009 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

161. A rare cause of intestinal obstruction due to an exophytic gastrointestinal stromal tumor of the small bowel

SEZER Y. A., YAĞCI M. A., HATİPOĞLU A. R., COŞKUN İ., ÇİÇİN İ., USTA U., et al.
Signa Vitae , cilt.4, sa.2, ss.32-34, 2009 (SCI-Expanded, Scopus) Creative Commons License identifier identifier

162. Implantation of central venous ports with chest catheter insertion via the subclavian vein in oncology patients In single center experience

KARAMUSTAFAOĞLU Y. A., YÖRÜK Y., TARLADAÇALIŞIR T., KOÇAL S., TİRYAKİ YAĞCI S., ÇİÇİN İ.
ACTA ONCOLOGICA TURCICA , cilt.45, sa.3, ss.105-108, 2009 (Hakemli Dergi)

163. The importance of using PET/CT investigation in case of recurrence in an ovarian cancer case with lymph node metastasis without any lesions that can be scanned via conventional methods

TANRIVERDİ Ö., Uzunoǧlu S., KARAGÖL H., ÇİÇİN İ., Coşar Alas R., Tokatli F., et al.
Journal of the Turkish German Gynecology Association , cilt.9, sa.3, ss.171-174, 2008 (Scopus, TRDizin) identifier identifier identifier

164. A cased of non-Hodgkin's lymphoma presenting as a large chest wall mass Göǧüs duvarinda büyük bir kitle şeklinde ortaya çikan non-Hodgkin lenfoma olgusu

Uzunoǧlu S., TANRIVERDİ Ö., KARAGÖL H., ÇİÇİN İ., Çaloǧlu V., Tokatli F.
Turk Onkoloji Dergisi , cilt.23, sa.4, ss.196-199, 2008 (Scopus, TRDizin) identifier

165. A case of gastric adenocarcinoma with rectal metastasis in the form of linitis plastica presenting as primary rectum carcinoma Rektuma linitis plastika şeklinde metastaz yapan ve primer rektum kanseri gibi görünen mide adenokarsinomu: Olgu sunumu

Uzunoǧlu S., ÇİÇİN İ., KARAGÖL H., Tanriverdi Ö., GENÇHELLAÇ H., USTA U.
Trakya Universitesi Tip Fakultesi Dergisi , cilt.25, sa.2, ss.160-163, 2008 (Scopus, TRDizin) identifier

166. The efficiency of single agent docetaxel in patients with platinum-refractory non-small cell lung carcinoma

UYGUN K., AKSU M. G., ÇİÇİN İ., KARAGÖL H., KOÇAK Z., Fayda M., et al.
Medical Oncology , cilt.25, sa.4, ss.408-414, 2008 (SCI-Expanded, Scopus) identifier identifier identifier

167. Adrenal insufficiency caused by bilateral adrenal macrometastases: A rare case with metastatic colon cancer

ÇİÇİN İ., Uzunoǧlu S., KARAGÖL H., Usta U., Temizöz O., ERMANTAŞ N.
Turk Onkoloji Dergisi , cilt.23, sa.2, ss.96-99, 2008 (Scopus, TRDizin) identifier identifier identifier

168. Inguinal lymph node as the only evidence of progressive lung cancer.

KOÇAK Z., SAYNAK M., ÖZ PUYAN F., ÇİÇİN İ., COŞAR R., ÇALOĞLU H. M., et al.
Revista Portuguesa de Pneumologia , cilt.14, sa.5, ss.709-713, 2008 (Hakemli Dergi) identifier

169. A case of gastric adenocarcinoma with rectal metastasis in the form of linitis plastica presenting as primary rectum carcinoma

Uzunoglu S., ÇİÇİN İ., KARAGÖL H., Tanriverdi O., GENÇHELLAÇ H., USTA U.
TRAKYA UNIVERSITESI TIP FAKULTESI DERGISI , cilt.25, sa.2, ss.160-163, 2008 (SCI-Expanded, Scopus, TRDizin) Sürdürülebilir Kalkınma identifier identifier

170. Inguinal lymph node as the only evidence of progressive lung cancer Gânglio inguinal como única evidência de cancro progressivo do pulmão

KOÇAK Z., SAYNAK M., ÖZ PUYAN F., ÇİÇİN İ., Cosar-Alas R., Caloglu M., et al.
Revista Portuguesa de Pneumologia , cilt.14, sa.5, ss.709-713, 2008 (Scopus) Creative Commons License identifier identifier identifier

171. Ovarian carcinosarcomas: Clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum

ÇİÇİN İ., Saip P., Eralp Y., Selam M., TOPUZ S., ÖZLÜK M. Y., et al.
Gynecologic Oncology , cilt.108, sa.1, ss.136-140, 2008 (SCI-Expanded, Scopus) identifier identifier identifier

172. Factors affecting the prognosis of breast cancer patients with brain metastases

Saip P., ÇİÇİN İ., Eralp Y., Kucucuk S., Tuzlali S., KARAGÖL H., et al.
Breast , cilt.17, sa.5, ss.451-458, 2008 (SCI-Expanded, Scopus) identifier identifier identifier

173. A case of non-Hodgkin's lymphoma presenting as a large chest wall mass

Uzunoglu S., TANRIVERDİ Ö., KARAGÖL H., ÇİÇİN İ., YÜRÜT ÇALOĞLU V., Tokatli F.
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.23, sa.4, ss.196-199, 2008 (ESCI, Scopus, TRDizin) Sürdürülebilir Kalkınma identifier

174. Hypertrophic osteoarthropathy associated with lung cancer: A case report Akciǧer kanserine baǧli hipertrofik osteoartropati: Olgu sunumu

Özen A., SAYNAK M., KOÇAK Z., Bayir-Angin G., Üregen B., Coşar-Alas R., et al.
Turk Onkoloji Dergisi , cilt.22, sa.3, ss.141-145, 2007 (Scopus, TRDizin) identifier

175. Paraneoplastic rheumatologic syndromes associated with non-small cell lung cancer: Case report and review of paraneoplastic rheumatologic syndromes Küçük hücreli dişi akciǧer kanseri ile ilişkili paraneoplastik romatolojik sendrom: Olgu sunumu ve paraneoplastik romatolojik sendromlara bir bakiş

Uzunoǧlu S., Karagöl H., Çiçin I., SAYNAK M.
Turk Onkoloji Dergisi , cilt.22, sa.3, ss.127-133, 2007 (Scopus, TRDizin) identifier

176. Extrapulmonary small-cell carcinoma compared with small-cell lung carcinoma: A retrospective single-center study

ÇİÇİN İ., KARAGÖL H., Uzunoglu S., UYGUN K., USTA U., KOÇAK Z., et al.
Cancer , cilt.110, sa.5, ss.1068-1076, 2007 (SCI-Expanded, Scopus) identifier identifier identifier

177. Efficient and safe application of a FOLFIRI/bevacizumab combination to a patient with locally advanced rectal cancer and severe chronic renal failure

ÇİÇİN İ., KARAGÖL H., Uzunoglu S., UYGUN K.
Onkologie , cilt.30, sa.1-2, ss.65, 2007 (SCI-Expanded, Scopus) identifier identifier identifier

178. Akciğer kanserine bağlı hipertrofik osteoartropati Olgu sunumu

ÖZEN A., SAYNAK M., KOÇAK Z., Bayır Angın G., Üregen B., COŞAR R., et al.
Turkish Journal of Oncology , cilt.22, sa.3, ss.141-145, 2007 (Hakemli Dergi) Sürdürülebilir Kalkınma

179. Paraneoplastic rheumatologic syndromes associated with non-small cell lung cancer: case report and review of paraneoplastic rheumatologic syndromes

Uzunoglu S., KARAGÖL H., ÇİÇİN İ., SAYNAK M.
TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.22, sa.3, ss.127-133, 2007 (ESCI, Scopus, TRDizin) Sürdürülebilir Kalkınma identifier

180. Isolated bone metastasis in testicular germ cell tumors: A case report and review of the literature

UYGUN K., KARAGÖL H., KOÇAK Z., ÇİÇİN İ., YALÇIN Ö., Caloglu M., et al.
Onkologie , cilt.29, sa.3, ss.93-95, 2006 (SCI-Expanded, Scopus) identifier identifier identifier

181. Colonic metastasis from carcinoma of the breast that mimicks a primary intestinal cancer

UYGUN K., KOÇAK Z., Altaner S., ÇİÇİN İ., Tokatli F., Uzal C.
Yonsei Medical Journal , cilt.47, sa.4, ss.578-582, 2006 (SCI-Expanded, Scopus) Creative Commons License identifier identifier identifier

182. Unusual metastatic site in a case of carcinoma of the hypopharynx: Nasal tip

KOÇAK Z., UYGUN K., Uzal M. C., ÇİÇİN İ., YALÇIN Ö.
Journal of Otolaryngology , cilt.34, sa.4, ss.250-252, 2005 (SCI-Expanded, Scopus) identifier identifier identifier

183. Fatal hepatic veno-occlusive disease in an adult patient with Wilms' tumour.

UYGUN K., KOÇAK Z., ÇİÇİN İ., Caloglu M.
Clinical oncology (Royal College of Radiologists (Great Britain)) , cilt.15, sa.6, ss.366, 2003 (SCI-Expanded, Scopus) identifier identifier identifier identifier

184. Staphylococcal pyomyositis in a patient with non-Hodgkin's lymphoma

Demir M., Çakir B., Vural O., Muammer Karakaş H., KARA M. U., ÇİÇİN İ.
Annals of Hematology , cilt.79, sa.5, ss.279-282, 1999 (SCI-Expanded, Scopus) identifier identifier identifier
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 88

1. The results of adding immunotherapy to chemotherapy in patients with small cell lung cancer: Registurk-Lung study-Real-world data

Cil T., Hacibekiroglu I., Uncu D., Isikdogan A., Ates O., Sendur M. A. N., et al.
Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, cilt.42, (Özet Bildiri) identifier

2. Perceptions and expectations: A study on prognostic perception and quality of life in patients with metastatic renal and bladder cancer.

Bolek H., Arslan C., BAŞARAN M., Cicin I., ÖZGÜROĞLU M., Tural D., et al.
Special Clinical Science Symposia, ELECTR NETWORK, 29 Mayıs 2024, cilt.42, (Özet Bildiri) identifier

3. Telisotuzumab vedotin monotherapy in Asian patients with c-Meteoverexpressing advanced non-small cell lung cancer

Horinouchi H., Camidge D. R., Bar J., Goldman J., Moiseenko F., Filippova E., et al.
Annual Meeting of the Japanese-Society-of-Medical-Oncology (JSMO), Fukuoka, Japonya, 16 - 18 Mart 2023, cilt.34, (Özet Bildiri) identifier

4. Patient preferences for use of archived biospecimens in Turkey

KUBİLAY TOLUNAY P., Erol C., Kahraman S., Tacar S. Y., ÖZCAN E., Basal F. B., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 2 - 06 Haziran 2023, cilt.41, (Özet Bildiri) identifier

5. Awareness and perceptions of clinical trials in patients with cancer and their families in Turkey

KUBİLAY TOLUNAY P., Erol C., Kahraman S., Tacar S. Y., ÖZCAN E., Basal F. B., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 2 - 06 Haziran 2023, cilt.41, (Özet Bildiri) identifier

6. Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo)

Vokes N. I., Gandara D. R., Sezer A., Kilickap S., Gumus M., Bondarenko I., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 2 - 06 Haziran 2023, cilt.41, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

7. Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met-overexpressing (OE) advanced non-small cell lung cancer (NSCLC).

Camidge D. R., Bar J., Horinouchi H., Goldman J. W., Moiseenko F. V., Filippova E., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 Haziran 2022, cilt.40, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

8. Clinical efficacy and safety of the BAT1706 (proposed bevacizumab biosimilar) compared with reference bevacizumab in patients with advanced nonsquamous NSCLC: A randomized, double-blind, phase III study.

Chen L., Trukhin D., Kolesnik O., David Gomez Rangel J. D., Cil T., Li X., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 Haziran 2022, cilt.40, (Özet Bildiri) identifier

9. Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC.

Yildirim M. E., Karaca M., Artac M., Cicin I., Geredeli C., Alacacioglu A., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 Haziran 2022, cilt.40, (Özet Bildiri) identifier

10. Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

Bilici A., Olmez O. F., Sezer A., Oksuzoglu B., Kaplan M. A., Karadurmus N., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 3 - 07 Haziran 2022, cilt.40, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

11. METASTATİK KOLOREKTAL KANSER TANILI 413 HASTANIN NGS (YENİ NESİL DİZİLEME) VERİLERİ; TEK MERKEZ DENEYİMİ

KÜÇÜKARDA A., ÇİÇİN İ.
8.TÜRK TIBBİ ONKOLOJİ KONGRESİ, Türkiye, 03 Kasım 2021, (Özet Bildiri) Sürdürülebilir Kalkınma

12. Telisotuzumab vedotin (teliso-v) monotherapy in patients with previously treated c-Met+ advanced non-small cell lung cancer.

Camidge D. R., Moiseenko F., ÇİÇİN İ., Horinouchi H., Filippova E., Bar J., et al.
Annual Meeting of the American-Association-for-Cancer-Research (AACR), Pennsylvania, Amerika Birleşik Devletleri, 10 Nisan - 21 Mayıs 2021, cilt.81, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

13. Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: KEYNOTE-598.

Sendur M. N., Reck M., Rodriguez-Abreu D., Park K., Lee D. H., Cicin I., et al.
Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 4 - 08 Haziran 2021, cilt.39, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

14. Real-world treatment outcomes from nationwide ONCO-colon Turkey registry in RAS wild-type patients treated with biologics first-line metastatic colorectal cancer.

KEFELİ U., Arslan C., Yildirim M. E., Isikdogan A., Karadurmus N., Karabulut B., et al.
Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 4 - 08 Haziran 2021, cilt.39, (Özet Bildiri) identifier

15. Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 ≥ 50%: Results from EMPOWER-Lung 1 study.

Gumus M., Chen C., Ivanescu C., Kilickap S., Bondarenko I., ÖZGÜROĞLU M., et al.
Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 4 - 08 Haziran 2021, cilt.39, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

16. Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥ 50%: EMPOWER-Lung 1 subgroup analysis.

ÖZGÜROĞLU M., Sezer A., Kilickap S., Gumus M., Bondarenko I., Gogishvili M., et al.
Virtual Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 4 - 08 Haziran 2021, cilt.39, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

17. AMEERA-3, a phase 2 trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (her2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies

Tolaney S., ÇİÇİN İ., Betancourt R., Chan A., Kaen D., Kaufman P., et al.
San Antonio Breast Cancer Virtual Symposium, ELECTR NETWORK, 8 - 11 Aralık 2020, cilt.81, (Özet Bildiri) identifier

18. Birinci Basamak İmmünoterapi Alan Metastatik Küçük Hücreli Dışı Akciğer Kanseri Hastalarında Yanıt Derinliği ile Yanıt Dayanıklılığı ve Genel Sağkalım İlişkisi

GÖKYER A., KÜÇÜKARDA A., ÇİÇİN İ.
4. ULUSAL İMMÜNOTERAPİ VE ONKOLOJİ KONGRESİ, Türkiye, 29 Ekim - 01 Kasım 2020, (Özet Bildiri) Sürdürülebilir Kalkınma

19. Evre 4 Akciğer Adenokarsinomlu 1081 Hastanın NGS (Next GenerationSequencing) Verileri

GÖKYER A., KÜÇÜKARDA A., TAŞTEKİN E., ÇİÇİN İ.
ESMO Highlights, Türkiye, 22 - 26 Eylül 2020, (Özet Bildiri)

20. Retrospective analysis of ribociclib and letrozole as first-line therapy in patients with hormone receptor (HR) positive metastatic breast cancer (MBC) within a managed access program (MAP) in Turkey.

Basaran G., Demirci U., Yildiz F., Cicin I., Aktas B. Y., Ozturk B., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020, cilt.38, (Özet Bildiri) identifier

21. Phase II trial of SAR439859 vs endocrine monotherapy in pre- and post-menopausal, estrogen receptor-positive (ER plus )/human epidermal growth factor receptor 2-negative (HER2-), locally advanced or metastatic breast cancer (BC) with prior exposure to hormonal therapies.

Tolaney S. M., Cicin I., Betancourt R., Chan A., Kaen D., Kaufman P. A., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 29 - 31 Mayıs 2020, cilt.38, (Özet Bildiri) identifier

22. Association of adverse events (AEs) with efficacy outcomes for cabozantinib (C) in patients (pts) with advanced hepatocellular carcinoma (aHCC) in the phase III CELESTIAL trial.

Abou-Alfa G. K., Meyer T., Cheng A., Cicin I., Bolondi L., Klumpen H. J., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

23. Trifluridine/tipiracil (FTD/TPI) in patients (pts) aged ≥65 years with metastatic gastric/gastroesophageal junction cancer (mGC/mGEJC): Subgroup analysis from TAGS.

Shitara K., Doi T., Hosaka H., Thuss-Patience P. C., Santoro A., Jimenez-Fonseca P., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 31 Mayıs - 04 Haziran 2019, cilt.37, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

24. Screening for germline variations of cancer related genes in patients with the diagnosis of different cancers and hereditary cancer predisposition syndromes

DEMİR S., TOZKIR H., GÜRKAN H., ATLI E., Eker D., TEZEL H. A., et al.
European Human Genetics Conference 2018, Milan, İtalya, 16 - 19 Haziran 2018, (Özet Bildiri)

25. C-2491 Relationship Between Prognostic Factors, Survival With Apparent Diffusion Coeficient in Breast Cancer

KARABULUT D., HACIOĞLU M. B., KULA O., TAŞTEKİN E., Süt N., ÇİÇİN İ., et al.
The 2018 European Congress of Radiology, Viyana, Avusturya, 28 Ocak - 04 Mart 2018, ss.2-3, (Özet Bildiri) Sürdürülebilir Kalkınma

26. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial.

Abou-Alfa G. K., Meyer T., Cheng A., El-Khoueiry A. B., Rimassa L., Ryoo B., et al.
Gastrointestinal Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Kostarika, 18 - 20 Ocak 2018, cilt.36, (Özet Bildiri) Sürdürülebilir Kalkınma identifier

27. SS-047 MEME KANSERLERİNDE ADC İLE PROGNOSTİK FAKTÖRLER, SAĞKALIM VE NEOANGİOGENEZİS İLİŞKİSİ

KARABULUT D., HACIOĞLU M. B., KULA O., TAŞTEKİN E., Süt N., ÇİÇİN İ., et al.
38. ULUSAL RADYOLOJİ KONGRESİ - 2017, Antalya, Türkiye, 31 Ekim - 04 Kasım 2017, ss.67-68, (Özet Bildiri) Sürdürülebilir Kalkınma

28. Meme Kanserlerinde ADC ile Prognostik Faktörler, Sağkalım ve Neoangiogenezis İlişkisi

KARABULUT D., HACIOĞLU M. B., KULA O., TAŞTEKİN E., SÜT N., ÇİÇİN İ., et al.
38. ULUSAL RADYOLOJİ KONGRESİ, Antalya, Türkiye, 31 Ekim - 04 Kasım 2017, (Özet Bildiri) Sürdürülebilir Kalkınma

29. Does the PD-L1 Status and TIL Intensity Change in NSCLC and Syncronous Brain Metastases? P2.02-073a

ÖZ A. B., Durak S., Batur S., YUMUK P. F., Çağlar H., BOZKURTLAR E., et al.
IASLC 18th World Congress of Lung Cancer, 15 - 18 Ekim 2017, (Özet Bildiri)

30. Kolorektal Kanserli Hastalarda Sitokrom P4501A1 (rs:1048943) Gen Polimorfizminin Araştırılması

AY A., ALKANLI N., GÜLYAŞAR T., SİPAHİ T., ÇİÇİN İ., KOÇAK Z., et al.
28-29. Ulusal Biyofizik Kongresi (Uluslararası Katılımlı), İstanbul, Türkiye, 6 - 09 Eylül 2017, cilt.9, ss.92, (Özet Bildiri) Sürdürülebilir Kalkınma

31. Characteristics of Turkish colorectal cancer patients and bevacizumab preference.

Cicin I., Gumus M., Uncu D., Ozkan M., Kilickap S., Elkiran T. E., et al.
53rd Annual Clinical Science Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Symposium on Old Targets, New Drugs - Her2 and MET, Illinois, Amerika Birleşik Devletleri, 2 - 07 Haziran 2017, cilt.35, (Özet Bildiri) identifier

32. Effectiveness and safety of LMWH treatment in patients with cancer diagnosed with nonhigh-risk venous thromboembolism (VTE): Results of the Turkish observational study (TREBECA).

Ozaslan E., Ozkan M., Cicin I., Benekli M., Kocer M., Uysal M., et al.
53rd Annual Clinical Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 2 - 07 Haziran 2017, cilt.35, (Özet Bildiri) identifier

33. Relationship Between the Genotypes of Glutathione S Transferase Gene Polymorphism and Serum Iron

AY A., ALKANLI N., GÜLYAŞAR T., SİPAHİ T., ÇİÇİN İ., KOÇAK Z.
4th International Congress of the Molecular Biology Association of Turkey, 27 - 29 Kasım 2015

34. The Relationship Between the Genotypes of CYP1A1 Gene Polymorphism and Serum Selenium Levels in Regard to Colorectal Cancer Risk

AY A., GÜLYAŞAR T., ALKANLI N., SİPAHİ T., ÇİÇİN İ., KOÇAK Z.
4th International Congress of the Molecular Biology Association of Turkey, 27 - 29 Kasım 2015 Sürdürülebilir Kalkınma

35. TRAKYA BÖLGESİ NDEKİ KOLOREKTAL KANSERLİ HASTALARDA SİTOKROM P450 1A1 GEN POLİMORFİZMİNİN GENOTİPLERİNİN MALONDİALDEHİT İLE İLİŞKİSİNİN ARAŞTIRILMASI

AY A., ALKANLI N., GÜLYAŞAR T., SİPAHİ T., ÇİÇİN İ., KOÇAK Z.
XIV. Ulusal Tıbbi Biyoloji ve Genetik Kongresi (Uluslararası Katılımlı), Muğla, Türkiye, 27 - 30 Ekim 2015, ss.246, (Özet Bildiri) Sürdürülebilir Kalkınma

36. Trakya Bölgesi ndeki Kolorektal Kanserli Hastalarda Sitokrom P4501A1 Gen Polimorfizminin Genotiplerinin Bakır Çinko Düzeyleri ve Bakır Çinko Oranı ile İlişkisi

AY A., GÜLYAŞAR T., ALKANLI N., SİPAHİ T., ÇİÇİN İ., KOÇAK Z.
27. Ulusal Biyofizik Kongresi, Malatya, Türkiye, 29 Eylül - 03 Ekim 2015, ss.89-90, (Özet Bildiri) Sürdürülebilir Kalkınma

37. Determination of lipid peroxidation levels in patient with colorectal cancer

AY A., ALKANLI N., GÜLYAŞAR T., SİPAHİ T., ÇİÇİN İ., KOÇAK Z.
The 2nd Middle East Molecular Biology Congress and Exhibition 2015, 17 - 20 Eylül 2015, (Özet Bildiri) Sürdürülebilir Kalkınma

38. The Relationship between Selenium Levels and Genotypes of the Cytochrome P450 1A1 Gene Polymorphisms in Colorectal Cancer

AY A., GÜLYAŞAR T., ALKANLI N., SİPAHİ T., ÇİÇİN İ., KOÇAK Z.
The 2nd Middle East Molecular Biology Congress and Exhibition 2015, 17 - 20 Eylül 2015

39. Association of The Role of Cytochrome P4501A1 Gene Polymorphism in Colorectal Cancer

AY A., ALKANLI N., GÜLYAŞAR T., SİPAHİ T., ÇİÇİN İ., KOÇAK Z.
9th International Physics Conference of the Balkan Physical Union, İstanbul, Türkiye, 24 - 27 Ağustos 2015 Sürdürülebilir Kalkınma

40. Association of Glutatyon S Transferaz M1 Gene Polymorphism Genotypes and Serum Iron Levels in Colorectal Cancer

AY A., ALKANLI N., GÜLYAŞAR T., SİPAHİ T., ÇİÇİN İ., KOÇAK Z.
9th International Physics Conference of the Balkan Physical Union, İstanbul, Türkiye, 24 - 27 Ağustos 2015

41. The Genotype Distrubition Of Cyp1a1 Gene Polymorphisms And Relationship Serum Selenium Levels With Colorectal Cancer In Trakya Region

AY A., ALKANLI N., GÜLYAŞAR T., SİPAHİ T., ÇİÇİN İ., KOÇAK Z., et al.
9th International Physics Conference of the Balkan Physical Union, İstanbul, Türkiye, 24 - 27 Ağustos 2015, (Özet Bildiri) Sürdürülebilir Kalkınma

42. Association Of Glutatyon S Transferaz M1 Gene Polimorphism Genotypes And Serum Iron Levels In Colorectal Cancer

AY A., ALKANLI N., GÜLYAŞAR T., SİPAHİ T., ÇİÇİN İ., KOÇAK Z.
9th International Physics Conference of the Balkan Physical Union (2015), İstanbul, Türkiye, 24 - 27 Ağustos 2015, ss.603, (Özet Bildiri)

43. The Genotype Distribution of CYP1A1 Gene Polymorphisms And Relationship Serum Selenium Levels With Colorectal Cancer in Trakya Region

AY A., ALKANLI N., GÜLYAŞAR T., SİPAHİ T., ÇİÇİN İ., KOÇAK Z., et al.
9th International Physics Conference of the Balkan Physical Union, İstanbul, Türkiye, 24 - 27 Ağustos 2015

44. The Genotype Distrubition of CYP1A1 Gene Polymorphism and Relationship Serum Selenium Levels With Colorectal Cancer in Trakya Region

AY A., ALKANLI N., GÜLYAŞAR T., SİPAHİ T., ÇİÇİN İ., KOÇAK Z.
9th International Physics Conference of the Balkan Physical Union, 24 - 27 Ağustos 2015, ss.605, (Özet Bildiri) Sürdürülebilir Kalkınma

45. Geographic variations of clinical characteristics in breast cancer: Analysis of Turkish National Breast Cancer Registry.

Kilickap S., Altundag K., Dumanli E., Gumus M., Uslu R., Ozyilkan O., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) identifier

46. Turkish National Colon Cancer Registry.

Benekli M., Dumanli E., Kilickap S., Uncu D., Aliustaoglu M., Cicin I., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) identifier

47. Turkish National Gastric Cancer Registry.

Buyukberber S., Dumanli E., Uncu D., Ozkan M., Uslu R., Dogu G. G., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) identifier

48. Effect of body mass index in gastric cancer patients: Analysis of Turkish national gastric cancer registry

Ciltas A., Karaca M., Uncu D., Ozkan M., Aliustaoglu M., Tekin S. B., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) identifier

49. Turkish National Breast Cancer Registry.

Altundag K., Dumanli E., Aliustaoglu M., Uncu D., Ozkan M., Cicin I., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) identifier

50. Association of obesity with breast cancer clinical and pathological factors: Analysis of Turkish National Breast Cancer Registry.

Coskun U., Altundag K., Aliustaoglu M., Uncu D., Ozkan M., Cicin I., et al.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, Amerika Birleşik Devletleri, 29 Mayıs - 02 Haziran 2015, cilt.33, (Özet Bildiri) identifier

51. Aktif Sigara İçiciliği EGFR Mutant Akciğer Adenokanseri Hastalarında Kötü Bir Prognostik Faktördür

ERDOĞAN B., KODAZ H., KARABULUT S., TOZKIR H., TANRIVERDİ Ö., ÇABUK D., et al.
21. Ulusal Kanser Kongresi, Türkiye, 22 - 26 Nisan 2015

52. Kolorektal Kanserin Metilentetrahidrofolat Redüktaz C677T Gen Polimorfizmi ile İlişkisinin Araştırılması

AY A., ALKANLI N., SİPAHİ T., GÜLYAŞAR T., ÇİÇİN İ., KARAL Ö.
26. Ulusal Biyofizik Kongresi, Tokat, Türkiye, 9 - 12 Eylül 2014, cilt.11, ss.50-51, (Özet Bildiri) Sürdürülebilir Kalkınma

53. Investigation of The Role of MTHFR A1298C Gene Polymorphism in Colorectal Cancer

AY A., ALKANLI N., SİPAHİ T., ÇİÇİN İ.
3rd International Molecular Biology and Biotechnology Congress, saraybosna, Bosna-Hersek, 2 - 06 Haziran 2014, ss.205, (Özet Bildiri) Sürdürülebilir Kalkınma

54. Turkish Breast Cancer Registry: A multicenter epidemiologic study

Coskun U., Gumus M., Uncu D., Ozkan M., Cicin I., Altundag K., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, Amerika Birleşik Devletleri, 30 Mayıs - 03 Haziran 2014, cilt.32, (Özet Bildiri) identifier

55. Pankreas kanserinin postoperatif tedavisi: Retrospektif değerlendirme

TÜRKKAN G., ÇUKURÇAYIR F., SAYNAK M., KOÇAK Z., İBİŞ K., NURLU D., et al.
11. Ulusal Radyasyon Onkolojisi Kongresi, Türkiye, 23 - 26 Nisan 2014, (Özet Bildiri) Sürdürülebilir Kalkınma

56. Pankreas kanserinin postoperative tedavisi Retrospektif değerlendirme

TÜRKKAN G., ÇUKURÇAYIR F., SAYNAK M., KOÇAK Z., İBİŞ K., NURLU D., et al.
XI. Ulusal Radyasyon Onkolojisi Kongresi, Türkiye, 24 - 26 Nisan 2014, (Özet Bildiri) Sürdürülebilir Kalkınma

57. Kemoterapiye bağlı hataların önlenmesi için yapılan eczacılık uygulamaları

KORUCU F. C., NAZLI H., ÇİÇİN İ.
5. Türk Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 19 - 23 Mart 2014, (Özet Bildiri)

58. Kolorektal, Akciğer ve Tiroid Karsinomlarında KRAS, EGFR ve BRAF Gen Mutasyonlarının Analizi: Trakya Üniversitesi Genetik Tanı Merkezi Deneyimleri.

Demirkan B., DEMİR S., GÜRKAN H., TOZKIR H., ÇİÇİN İ., GÜLDİKEN S., et al.
Erişkin Yaşta Görülen Genetik Hastalıklar Sempozyumu, İstanbul, Türkiye, 6 - 07 Aralık 2013, (Özet Bildiri)

59. Karnitin ve dimetiksülfoksitin (DMSO) tek başlarına ve birlikte doksorubisin ekstravazasyon tedavisindeki etkinliklerinin değerlendirilmesi

UZUNOĞLU S., COŞAR R., ÇİÇİN İ., İBİŞ K., ALTANER Ş., BENLİER E., et al.
19. Ulusal Kanser Kongresi, Türkiye, 19 - 23 Nisan 2012, (Özet Bildiri)

60. Süperior sulkus tümörlerinde preoperatif kemoradyoterapi sonrası inoperabl hastalığı belirlemek için konvansiyonel görüntüleme yöntemleri yeterli mi Olgu sunumu sayfa 218 2013 Antalya 19 23 Nisan 2013

ÇUKURÇAYIR F., TÜRKKAN G., SAYNAK M., KOÇAK Z., KARAMUSTAFAOĞLU Y. A., SARIKAYA A., et al.
20. Ulusal Kanser Kongresi, Türkiye, 19 - 23 Nisan 2013

61. Non Metastaik Serviks Kanserinde Tedavi Sonuçlarımız

ÖZEN A., ÇUKURÇAYIR F., COŞAR R., ÇİÇİN İ., ÜREGEN B., PARLAR Ş., et al.
X. Ulusal Radyasyon Onkolojisi Kongresi, Türkiye, 19 - 23 Nisan 2012, (Özet Bildiri) Sürdürülebilir Kalkınma

62. Non metastatik serviks kanserinde tedavi sonuçlarımız

ÖZEN A., ÇUKURÇAYIR F., COŞAR R., ÇİÇİN İ., ÜREGEN B., PARLAR Ş., et al.
X. Ulusal Radyasyon Onkolojisi Kongresi, Türkiye, 19 - 23 Nisan 2012, (Özet Bildiri)

63. Kontrastlı Bilgisayarlı Tomografi Çekimi Sonrası Kontrast Madde Nefropatisi Gelişme Riski Ve Prediktif Faktörler

UZUNOĞLU S., TÜRKMEN E., ERDOĞAN B., ÇİÇİN İ., SARI A.
4. Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 21 - 25 Mart 2012, ss.102

64. Primeri Bilinmeyen Tümörlerin Klinik Patolojik Demografik Özellikleri ve Tedavi Sonuçlarının Retrospektif Analizi

UZUNOĞLU S., TÜRKMEN E., ERDOĞAN B., ÇİÇİN İ., SARI A.
4. Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 21 - 25 Mart 2012

65. İkinci Seri Kemoterapi uygulanan Pankreotikobilier kanserli hastaların değerlendirilmesi Tek Merkez Deneyimi

UZUNOĞLU S., TÜRKMEN E., ERDOĞAN B., ÇİÇİN İ., SARI A.
4. Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 21 - 25 Mart 2012, ss.117 Sürdürülebilir Kalkınma

66. Küçük Hücreli Akciğer Kanseri Tedavisi Sırasında Görülen Guillain Barre Sendromu

UZUNOĞLU S., TÜRKMEN E., ERDOĞAN B., ÇİÇİN İ., SARI A.
4. Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 21 - 25 Mart 2012 Sürdürülebilir Kalkınma

67. Testiküler Matür Teratom Zemininde Gelişen Küçük Hücreli Karsinom Olgu Sunumu

UZUNOĞLU S., TÜRKMEN E., ERDOĞAN B., ÇİÇİN İ., SARI A.
4. Tıbbi Onkoloji Kongresi, Antalya, Türkiye, 21 - 25 Mart 2012

68. TESTİKÜLER MATÜR TERATOM ZEMİNİNDE GELİŞEN KÜÇÜKHÜCRELİ KARSİNOM OLGU SUNUMU

TÜRKMEN BEKMEZ E., ERDOĞAN B., UZUNOĞLU S., KILIÇ N., USTA U., ÖZEN A., et al.
4. Tıbbi Onkoloji Kongresi, Türkiye, 21 - 25 Mart 2012, (Özet Bildiri)

69. Midenin Non Fonksiyone iyi Diferansiye Nöroendokrin Tümörünün Karaciğer Metastazı ile Prezantasyonu

SEZER Y. A., SAĞIROĞLU T., ÇİÇİN İ., YALTA T. D., TAŞTEKİN E.
9. Medikal-Cerrahi Endokrinoloji Mezuniyet sonrası Eğitim Kursu, Türkiye, 2 - 05 Aralık 2010

70. A Case of an Ileus by a Gastrointestinal Stromal Tumors of the Small Intestine

SEZER Y. A., YAĞCI M. A., HATİPOĞLU A. R., COŞKUN İ., ÇİÇİN İ., USTA U., et al.
10th European Congress of Trauma and Emergency Surgery, Antalya, Türkiye, 13 - 17 Mayıs 2009, cilt.35, ss.1-188

71. Karın Duvarı İnflamatuvar Myofibroblastik Tümörü

YAĞCI M. A., SEZER Y. A., YELDAN E., COŞKUN İ., USTA U., ÇİÇİN İ., et al.
Ege Cerrahi Kongresi, İzmir, Türkiye, 23 - 26 Nisan 2009

72. İLERİ EVRE KÜÇÜK HÜCRELİ DIŞI AKCİĞER KANSERİNDE ANJİYOGENİK ANTİANJİYOGENİK DENGENİN SAĞKALIM SÜRELERİNE ETKİSİ

DEMİR V., DEMİR A. M., ÇİÇİN İ., PAMUK G. E., ÖZTÜRK E., TUNCAY Ç.
34. Ulusal Hematoloji Kongresi, İzmir, Türkiye, 8 - 11 Ekim 2008, (Özet Bildiri)

73. Onkoloji hastalarında göğüs duvarı yerleşimli santral venöz kateter uygulamaları tek merkez deneyimi

KARAMUSTAFAOĞLU Y. A., TARLADAÇALIŞIR T., YAVAŞMAN İ., KOÇAL S., REYHAN G., KUZUCUOĞLU M., et al.
4. Ulusal Torasik Onkoloji Kongresi, Antalya, Türkiye, 19 - 22 Haziran 2008

74. Akciğer kanserli bir olguda ilk progresyon bölgesi İnguinal lenf nodu

KOÇAK Z., SAYNAK M., ÖZ PUYAN F., Bayır-Angın G., UZUNOĞLU S., ÇİÇİN İ., et al.
8. Ulusal Radyasyon Onkolojisi Kongresi, Antalya, 2008., Antalya, Türkiye, 19 - 23 Nisan 2008, ss.113 Sürdürülebilir Kalkınma

75. Lokal ileri pankreas kanseri tanılı hastalarda kemoradyoterapi ön sonuçları

SAYNAK M., KOÇAK Z., Tokatlı F., Bayır G., ÇİÇİN İ., ÇALOĞLU H. M., et al.
7. Ulusal Radyasyon Onkolojisi Kongresi, Muğla, 2006, Muğla, Türkiye, 19 - 23 Nisan 2006, ss.71, (Tam Metin Bildiri) Sürdürülebilir Kalkınma

76. Küratif rezeksiyon yapılmış mide kanserinin tedavisinde postoperatif kemoradyoterapi

Bayır G., KOÇAK Z., Karagöl H., SAYNAK M., ÇİÇİN İ., UYGUN K., et al.
7. Ulusal Radyasyon Onkolojisi Kongresi, Muğla, 2006., Muğla, Türkiye, 19 - 23 Nisan 2006, ss.131-132 Sürdürülebilir Kalkınma

77. The treatment results of patients with extrapulmoner and pulmoner small cell cancer

Uygun K., Cicin I., Karagol H., Uzunoglu S., KOÇAK Z., Caloglu M., et al.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.240, (Özet Bildiri) identifier

78. Second line chemotherapy in non-small-cell lung carcinoma: A single-institution experience

Uygun K., Cicin I., Karagol H., Uzunoglu S., SAİP P. M.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.239, (Özet Bildiri) identifier

79. The comparison of weekly and 3-weekly cisplatin chemotherapy concurrent with radiotherapy in patients with previously untreated inoperable non-metastatic SCCHN

Uygun K., Karagol H., Caloglu M., Cicin I., Caloglu V. Y., Uzunoglu S., et al.
31st Congress of the European-Society-for-Medical-Oncology, İstanbul, Türkiye, 29 Eylül - 03 Ekim 2006, cilt.17, ss.182, (Özet Bildiri) identifier

80. T1 tümörlü meme karsinomlu olgularda hastalıksız ve genel sağkalıma etki eden faktörlerin analizi

Tokatlı F., COŞAR R., Karagöl H., Uğuzalp M., ÇİÇİN İ., UZAL M. C., et al.
VIII. Ulusal Meme Hastalıkları Kongresi, İstanbul, 2005, İstanbul, Türkiye, 21 - 24 Eylül 2005, ss.266

81. Histolojik ve nükleer gradı III olan meme karsinomlu olguların genel özellikleri ve sağkalıma etki eden faktörlerin analizi

Karagöl H., Tokatlı F., COŞAR R., Uğuzalp M., UZAL M. C., ÇİÇİN İ., et al.
VIII. Ulusal Meme Hastalıkları Kongresi, İstanbul, 2005., İstanbul, Türkiye, 21 - 24 Eylül 2005, ss.324

82. Aortic stiffness is associated with hemodialysis induced hypotension in patients undergoing chronic hemodialysis

UZUNOĞLU S., TÜRKMEN E., ERDOĞAN B., ÇİÇİN İ., SARI A.
ESC CONGRESS 2005, 3 - 07 Eylül 2005, cilt.13, ss.73-78 identifier identifier identifier

83. Association of aortic stiffness and left ventricular diastolic function with microalbuminuria in type 2 diabetic patients

UZUNOĞLU S., TÜRKMEN E., ERDOĞAN B., ÇİÇİN İ., SARI A.
ESC CONGRESS 2005, 3 - 07 Eylül 2005 Sürdürülebilir Kalkınma

84. Metastatik meme kanserli hastalarda beyin metastazı gelişimi ile ilgili faktörler

Karagöl H., UYGUN K., ÇİÇİN İ., COŞAR R., YÜRÜT ÇALOĞLU V., ÇALOĞLU H. M., et al.
XVI. Ulusal Kanser Kongresi, Antalya, 2005, Antalya, Türkiye, 20 - 24 Nisan 2005, ss.9-10 Sürdürülebilir Kalkınma

85. Meme kanserinde antrasiklin temelli adjuvan kemoterapinin etki toksisite profili ile vücut kitle indeksinin ilişkisi

Karagöl H., UYGUN K., ÇİÇİN İ., YÜRÜT ÇALOĞLU V., COŞAR R., ÇALOĞLU H. M., et al.
XVI. Ulusal Kanser Kongresi, Antalya, 2005., Antalya, Türkiye, 20 - 24 Nisan 2005, ss.10 Sürdürülebilir Kalkınma

86. Rektal adenokarsinomalı olguda orta uyluk bölgesi cildine metastaz

UYGUN K., Karagöl H., Bilgi S., ÇİÇİN İ., Tokatlı F., COŞAR R., et al.
XVI. Ulusal Kanser Kongresi, Antalya, 2005, Antalya, Türkiye, 20 - 24 Nisan 2005, ss.48-49

87. Metastatik meme kanserli hastalarda tedavi sonuçları ve prognostik faktörler

Karagöl H., UYGUN K., ÇİÇİN İ., COŞAR R., YÜRÜT ÇALOĞLU V., ÇALOĞLU H. M., et al.
XVI. Ulusal Kanser Kongresi, Antalya, 2005, Antalya, Türkiye, 20 - 24 Nisan 2005, ss.19 Sürdürülebilir Kalkınma

88. Distribution of Haptoglobin Subtypes in a Turkish Population from Edirne East Trakya Turkey

ÇİÇİN İ., DEMİR A. M., VURAL Ö., TURGUT B., VURKUN M.
7th Congress of European Hematology Association, 09 Haziran 2002
Kitaplar 12

1. Prostat Kanser Biyobelirteçleri

GÖKYER A., KÜÇÜKARDA A., ÇİÇİN İ.
Prostat Kanseri Yönetimi, AHMET BİLİCİ, Editör, EMA Tıp Kitabevi Yayıncılık Tic. Ltd. Şti., ss.77-96, 2020

2. Gastrointestinal Tümörlerde Nütrisyonel Tedavi

GÖKYER A., KÜÇÜKARDA A., ÇİÇİN İ.
Son Dönem Kanser Hastasında Nütrisyonel Tedavi, , Editör, Türkiye Klinikleri, ss.41-44, 2020 Sürdürülebilir Kalkınma

3. Yaşlı Kanser Hastalarında İmmünoterapi

GÖKYER A., KÜÇÜKARDA A., ÇİÇİN İ.
Geriatrik Onkoloji, , Editör, Türkiye Klinikleri, ss.106-109, 2020

4. Pregnancy and Gastrointestinal Cancers.

ÇİÇİN İ., ALTUN G., SEZER Y. A., TUNÇBİLEK N., Ezgi Cisil E.
Textbook of Gastrointestinal Oncology (pp. 655-661)., Philip A. Philip Suayib Yalcin, Editör, Springer, Cham., Switzerland AG, ss.1-38, 2019

5. Pregnancy and Gastrointestinal Cancers

ÇİÇİN İ., altun durmuş g., TUNÇBİLEK N., erdoğan e. Ç.
Textbook of Gastrointestinal Oncology, Suayib YalcinPhilip A. Philip, Editör, Springer, ss.655-661, 2019

6. Özel Durumlar

GÖKYER A., KÜÇÜKARDA A., ÇİÇİN İ.
İmmunoterapilerde Yan Etki Yönetimi, İrfan Çiçin, Editör, Türkiye Klinikleri, ss.169-175, 2019

7. İmmünoterapilerin Nadir Toksisiteleri ve Yönetimi

HACIOĞLU M. B., ÇİÇİN İ.
İmmünoterapilerde Yan Etki Yönetimi, İrfan Çiçin, Editör, Türkiye Klinikleri, Ankara, ss.120-144, 2019

8. Gebelikte Kanser Tedavisi

Hacıbekiroğlu B., ERDOĞAN B., ÇİÇİN İ.
Güneş Tıp Kitapevleri, Ankara, 2017 Sürdürülebilir Kalkınma

9. GEBELİK VE SARKOMLAR

HACIOĞLU M. B., ERDOĞAN B., ÇİÇİN İ.
GEBELİKTE SARKOM TEDAVİSİ, GÜNEŞ TIP KİTAPEVİ, ss.195-207, 2017

10. GEBELİK VE SARKOMLAR

Hacıoğlu M. B., Erdoğan B., Çiçin İ.
GEBELİKTE KANSER TEDAVİSİ, İRFAN ÇİÇİN, SADETTİN KILIÇKAP, PINAR SAİP, NİLÜFER GÜLER, Editör, Güneş Tıp Kitabevi, Ankara, ss.195-205, 2017 Creative Commons License Sürdürülebilir Kalkınma

11. Bone-Directed Therapy and Breast Cancer: Bisphosphonates, Monoclonal Antibodies, and Radionuclides

ERDOĞAN B., ÇİÇİN İ.
BREAST DİSEASE Management and Terapies Volume 2, Adnan Aydıner, Abdullah İğci, Atilla Soran, Editör, Springer, ss.695-710, 2016

12. Meme Kanseri

ERDOĞAN B., ÇİÇİN İ.
Cleveland Klinik İç Hastalıkları Yoğunlaştırılmış Gözden Geçirme, James K. Stoller, Franklin A. Michote, Brian F. Mandell, Çeviri Editörü Ahmet Muzaffer Demir, Editör, İstanbul Tıp Kitapevi, İstanbul, ss.293-301, 2014
Metrikler

Yayın

284

Yayın (WoS)

198

Yayın (Scopus)

168

Atıf (WoS)

6833

H-İndeks (WoS)

28

Atıf (Scopus)

7014

H-İndeks (Scopus)

25

Atıf (TrDizin)

3

H-İndeks (TrDizin)

1

Atıf (Diğer Toplam)

6

Açık Erişim

25
BM Sürdürülebilir Kalkınma Amaçları